Introduction:
The Greek words are "athero," meaning gruel or wax, and "sclerosis," meaning hardening or induration. These terms describe the necrotic core area at the base of the atherosclerotic plaque. The morphologies of fatty streaks to fibroatheromas (FAs) and advanced plaques complicated by bleeding, calcification, ulceration, and thrombosis were the main topics of the early pathologic descriptions of atherosclerotic lesions. The condition known as atherosclerosis is typified by the buildup of lipids, fibrous materials, and calcium in the major arteries. Endothelium activation starts this process, followed by a series of actions that suggest vessel narrowing and the activation of inflammatory pathways that create atheroma plaque. When combined, these mechanisms contribute to cardiovascular problems, which continue to be the world's leading cause of mortality.
What Is Atherosclerosis?
Atherosclerosis is a disease of the arterial wall that affects the major conduit arteries at vulnerable locations. It starts with oxidation, alteration, and retention of fat, which leads to long-term inflammation, and eventually, thrombosis or stenosis. Atherosclerotic lesions can result in thrombotic blockage of the major conduit arteries leading to the heart, brain, legs, and other organs, or they can produce stenosis with potentially fatal distal ischemia. The intima, the inner lining of the arteries, is where lesions first appear. Over time, they spread to the media and adventitia, affecting the entire arterial wall. Over 3,500 years have passed since atherosclerosis first appeared in humans; the illness manifested itself in Egyptian mummies and displayed the same pathologic characteristics as it does now. Atherosclerosis can be exacerbated or precipitated by factors affecting inflammation and low-density lipoprotein (LDL) particles.
What Is the Classification of Atherosclerosis?
Six numerical categories make up the classification:
-
Type I: It comprises early lesions with adaptive intimal thickening.
-
Type II: It includes fatty streaks.
-
Type III: It includes transitional or intermediate lesions.
-
Type IV: It includes atheromas.
-
Type V: It includes fibroatheromas or atheromas with thick fibrous caps.
-
Type VI: It includes complicated plaques with surface defects, hematoma, hemorrhage, and thrombosis.
A modified version of the AHA (American Heart Association) classification was created to incorporate significant pathologic lesions, such as plaque erosion and calcified nodules, unrelated to plaque rupture and responsible for luminal thrombosis. This revised categorization replaces the numerical AHA (American Heart Association) lesions categories I through IV with descriptive terms, such as fibroatheroma, pathologic intimal thickening (PIT), adaptive intimal thickening, and intimal xanthoma.
What Are the Symptoms?
Usually, there are no symptoms associated with mild atherosclerosis. Typically, atherosclerosis symptoms do not appear until an artery becomes so constricted or blocked that it cannot adequately provide blood to tissues and organs. A blood clot can occasionally totally stop blood flow. The clot can break apart and cause a stroke or heart attack. Depending on which arteries are impacted, atherosclerosis can present with mild to severe symptoms:
-
A person may have pressure or pain in the chest (angina) if they have atherosclerosis in the heart arteries.
-
Atherosclerosis in the blood vessels supplying the brain can cause sudden numbness or paralysis in the arms or legs, slurred or difficult speech, transient blindness in one eye, and drooping facial muscles may experience claudication, leg pain during walking, or reduced blood pressure in a limb affected by peripheral artery disease if they have atherosclerosis in the arteries that supply arms and legs.
-
Hypertension or renal failure could occur if the arteries supplying the kidneys are clogged with plaque.
What Are the Most Common Risk Factors?
The most common risk factors include:
-
Genetic predisposition.
-
Obesity.
-
Diabetes mellitus.
-
Tobacco use and hypertension.
The precise biochemical mechanisms behind these risk factors' actions are yet unknown.
Research of coronary artery lesions has contributed significantly to the understanding of the main features of human atherosclerosis, with research of closely related lesions in the carotid arteries and aorta also playing a key role. Studies of genetically modified mice and other animal species have shown that different cell types within the lesion, inflammatory response elements, and lipid metabolism components all play a role in experimental atherosclerosis. These investigations on animals have shown that the formation of lesions is closely regulated by inflammatory processes, to which both innate and adaptive immune systems make major contributions.
Atherosclerosis treatment alters the clinical course, plaque size, content, and biological activity. Regarding five key metrics, lipid therapies accessible to all practitioners have positively altered atherosclerosis. Clinical event risk, plaque size, cellular makeup, chemical composition, and biological activity related to cholesterol metabolism and inflammation are the first five factors to consider.
What Are the Treatments for Atherosclerosis?
Duration and Impact of Risk Reduction Brought on by Lipid Treatments:
Statin therapy can produce clinical benefits in as few months. In two studies, a decrease in the risk of clinical events happened after four to six months and after one month in a post hoc analysis from one of those trials in patients undergoing rigorous statin treatment following acute coronary syndromes. This suggests that significant alterations in plaque tissue caused by statins after three to four months of treatment may have therapeutic advantages. Since only some clinical trials will evaluate plaque alterations in histology versus therapeutic benefit, rigorous validation of this relationship is unlikely. Rather, evidence is likely to be gathered through clinical studies to contrast treatment-induced alterations in plaque pictures with alterations in clinical outcomes.
Future Prospects for Treating Atherosclerosis:
The all-encompassing effects of statins on plaque with partial control of atherosclerosis suggest that new medication regimens will successfully treat atherosclerosis and dramatically alter the course and risk of clinical events associated with the disease. Future gains could exceed 70 percent, as opposed to the current typical maximum of roughly 40 percent. The study results presented here can help the physician choose targets for upcoming treatments to minimize residual clinical disease risks while controlling residual post-statin aberrations in arterial tissues and plaques.
Conclusion:
Data from recent clinical trials on the pathophysiology of advanced-stage arterial lesions of atherosclerosis show that within one to four months, statin treatment can start to change the composition of plaque and reduce its size, which will also lower the risk of developing clinical cardiovascular disease. Consequently, Stary's pragmatic definition of plaque regression is met by atherosclerosis. This disease was previously thought to be unavoidably progressing, as it may be significantly treated to change the arterial lesions and lessen their clinical effects. Licensed physicians in practice can achieve these advantages by combining prescribed medications with sensible eating, physical activity, managing weight, and quitting smoking.
